Acute Myeloid Leukaemia (AML) with Retinoic acid receptor-gamma (RARG) fusions have similarities to Acute Promyelocytic Leukemia (APL) but are not responsive to standard APL treatments. Here, the authors show the specific molecular mechanisms lead by RARG fusions in AML driving leukemogenesis and as potential therapeutic targets.
